Skip to content

Clinical trials

Phase 2 Squamous Intraepithelial Lesions trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Squamous Intraepithelial Lesions Phase: Phase 2 Clear all

24 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20061
20075
20131
20152
20161
20171
20182
20211
20231
20242
20251
20264

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed13
Recruiting4
Unknown status3
Not yet recruiting2
Terminated1
Withdrawn1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
AIDS Malignancy Consortium3
Newish Biotech (Wuxi) Co., Ltd.2
The Center for Clinical and Cosmetic Research2
Tigris Pharmaceuticals2
Amplexd Therapeutics, Inc.1
Brugmann University Hospital1
Department of Medical Services Ministry of Public Health of Thailand1
Gynecologic Oncology Group1
Inovio Pharmaceuticals1
National Cancer Institute (NCI)1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Squamous Intraepithelial Lesions24
Uterine Cervical Dysplasia10
Papillomavirus Infections5
Atypical Squamous Cells of the Cervix4
Anus Neoplasms3
Precancerous Conditions3
Carcinoma, Squamous Cell2
Skin Neoplasms2
Uterine Cervical Neoplasms2
Bowen's Disease1

Trials

Showing 51 to 24 of 24. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.